|
|
 |
|
|
|
|
 |
Tumor Necrosis Factor-α –1031 T/C Polymorphism Is Associated with Smaller and More Proatherogenic Low Density Lipoprotein Particles in Patients with Rheumatoid Arthritis
JOAN-CARLES VALLVÉ, SILVIA PAREDES, JOSEFA GIRONA, KATIA ULIAQUE, JOSEP RIBALTA, EVA HURT-CAMEJO, and LLUÍS MASANA
ABSTRACT. Methods. From a sample of 100 patients with RA and 100 controls, we used the strategy of "recruit by genotype" to select 30 patients with RA: 15 carriers of the rare allele (C) and 15 homozygous for the more frequent allele (T). These were matched with 30 controls. Plasma lipoprotein profile including size distribution of lipoproteins was determined using nuclear magnetic resonance spectrometry. LDL susceptibility to oxidation was assessed by diene formation. The LDL affinity for extracellular matrix was determined using electrophoretic mobility shift assay. Genotyping was performed by SnapShot. Results. Compared to TT patients with RA, carriers of the C allele had (1) LDL particles significantly smaller [20.74 (0.68) nm vs 21.18 (0.52), p < 0.02]; (2) LDL particles with a greater affinity for the proteoglycans (i.e., with a lower Kd) [197.26 (123.98) nmol/l vs 259.26 (139.31), p = 0.05]; and (3) LDL particles with significantly greater susceptibility to oxidation [shorter lag phase: 47 (20.01) min vs 74 (41.8), p < 0.03, and higher maximal rate of diene production: 3.1 (0.5) mol/min vs 2.6 (0.95), p < 0.05]. None of these differences was observed in the control group. Conclusion. In patients with RA, genetic variability in the TNF-α gene is associated with smaller LDL particles that have a greater affinity for extracellular matrix and higher susceptibility to oxidation. Because these characteristics are associated with a greater risk of atherosclerosis, identification of such predisposition in patients with RA could help in implementing early preventive intervention measures against cardiovascular disease. (First Release July 15 2008; J Rheumatol 2008;35:1697-703) Key Indexing Terms:
LIPOPROTEINS
From Unitat de Recerca de Lípids i Arteriosclerosi, Facultat de Medicina, Universitat Rovira i Virgili, Reus, Catalonia, Spain; and Cell Biology and Biochemistry, AstraZeneca, Lund, Sweden. Funded in part by ISCIII-FIS PI030786 and CIBERDEM. J-C. Vallvé, PhD; S. Paredes, PhD; J. Girona, PhD; K. Uliaque, PhD; J. Ribalta, PhD, Unitat de Recerca de Lípids I Arteriosclerosi, Facultat de Medicina, Universitat Rovira I Virgili; E. Hurt-Camejo, PhD, Cell Biology and Biochemistry, AstraZeneca; L. Masana, MD, PhD, Unitat de Recerca de Lípids I Arteriosclerosi, Facultat de Medicina, Universitat Rovira I Virgili. Address reprint requests to Dr. J-C. Vallvé, Facultat de Medicina de Reus, Universitat Rovira i Virgili, C/Sant Llorenç 21, 43201 Reus, Catalunya, Spain. E-mail: jc.vallve@urv.cat Accepted for publication April 14, 2008. |
